Ken Griffin Relmada Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $4.36 $55,429 - $105,076	24,100 Added 56.05%	67,100 $217,000
Q2 2024 Aug 14, 2024	BUY	$2.93 - $4.94 $9,669 - $16,302	3,300 Added 8.31%	43,000 $129,000
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $40,300 - $88,400	13,000 Added 48.69%	39,700 $184,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $17,885 - $30,806	-7,300 Reduced 21.47%	26,700 $110,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $153,264 - $234,222	-61,800 Reduced 64.51%	34,000 $102,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $29,748 - $47,436	-13,400 Reduced 12.27%	95,800 $235,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $298,144 - $633,556	-133,100 Reduced 54.93%	109,200 $246,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $473,711 - $7.82 Million	-218,300 Reduced 47.39%	242,300 $845,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $6.01 Million - $12.1 Million	328,200 Added 247.89%	460,600 $17.1 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $83M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.